CCM
GHDX

Credo Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

Credo Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$13K Buy
460
+153
+50% +$4.86K 0.06% 159
2013
Q3 		$9K Hold
307
– – 0.02% 161
2013
Q2 		$10K Buy
+307
New +$10.1K 0.01% 157

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Credo Capital Management's GHDX Position: Q4 2013 in Review

Credo Capital Management increased its Genomic Health, Inc. (GHDX) stake by 50% in Q4 2013, buying an estimated $4.86K and bringing the position to 460 shares worth $13K. The position accounts for 0.06% of the portfolio, ranked #159.

Credo Capital Management first reported a position in GHDX in Q2 2013 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold GHDX as of Q4 2013.

  • Credo Capital Management held 460 shares of Genomic Health, Inc. worth $13K as of Q4 2013.
  • Credo Capital Management bought 153 Genomic Health, Inc. shares in Q4 2013, an estimated $4.86K.
  • Genomic Health, Inc. made up 0.06% of Credo Capital Management's portfolio in Q4 2013, its #159 holding.
  • Credo Capital Management first reported a position in Genomic Health, Inc. in Q2 2013 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2013.

Based on Credo Capital Management's 13F filing for Q4 2013, filed 24 Jan 2014.